<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03656614</url>
  </required_header>
  <id_info>
    <org_study_id>Reversal Neuromuscular Block</org_study_id>
    <nct_id>NCT03656614</nct_id>
  </id_info>
  <brief_title>Reversal of Residual Neuromuscular Blockade at Train-of-four Ratio 0.3 With Sugammadex and Neostigmine</brief_title>
  <official_title>Dose Finding Study for Reversal of Vecuronium-induced Neuromuscular Blockade at Train-of-four Ratio 0.3 With Sugammadex and Neostigmine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou General Hospital of Guangzhou Military Command</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou General Hospital of Guangzhou Military Command</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to estimate the optimal dose of sugammadex and neostigmine reversal&#xD;
      of a vecuronium-induced residual neuromuscular block at train-of-four ratio 0.3.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sugammadex is a modified γ-cyclodextrin compound that reverses the neuromuscular blockade&#xD;
      produced by steroidal nondepolarizing muscle relaxants such as rocuronium,vecuronium and&#xD;
      pipecuronium by encapsulating them, making them unavailable to interact with the nicotinic&#xD;
      acetylcholine receptors at the neuromuscular junction.However, residual neuromuscular blocks&#xD;
      between reappearance of T4 and train-of-four ratio (TOFR)=0.5 are more frequent in clinical&#xD;
      practice compared with profound or deep blocks and have not been investigated for sugammadex&#xD;
      previously.&#xD;
&#xD;
      Unlike neostigmine, sugammadex is efficacious in reversing profound (no responses to either&#xD;
      train-of-four (TOF) or posttetanic count stimulation) or deep (posttetanic count of 1 or 2)&#xD;
      neuromuscular block (NMB) in doses of 16 and 4 mg/kg, respectively. However, shallow&#xD;
      neuromuscular blocks are more frequent in clinical practice compared with profound or deep&#xD;
      blocks and have not been investigated for sugammadex previously.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 26, 2018</start_date>
  <completion_date type="Actual">June 30, 2019</completion_date>
  <primary_completion_date type="Actual">June 28, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Time to TOF 0.9 after the administration of reversal agent</measure>
    <time_frame>the general anesthesia time 1 hour at least</time_frame>
    <description>The time to achieve TOF (Train of Four stimulation) ratio to 0.9 following the investigational drug or placebo administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of reparalysis</measure>
    <time_frame>approximately 1 hour</time_frame>
    <description>Determining whether patients receiving reversal agent will have a train-to-four ratio &lt;0.8 during total recovery time (from TOF reach 0.9 first time to post-anaesthesia care unit (PACU) departure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of adverse event</measure>
    <time_frame>the general anesthesia and recovery time 2 hours at least</time_frame>
    <description>Documenting whether patients will have some adverse events(such as hypoxia bradycardia nausea and vomiting) from anesthesia commence to PACU departure.</description>
  </secondary_outcome>
  <number_of_groups>11</number_of_groups>
  <enrollment type="Actual">121</enrollment>
  <condition>Neuromuscular Blockade</condition>
  <arm_group>
    <arm_group_label>sugammadex 0.125</arm_group_label>
    <description>Sugammadex group: sugammadex 0.125 mg/kg IV once at the reappearance of TOF 0.3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex 0.25</arm_group_label>
    <description>Sugammadex group: sugammadex 0.25 mg/kg IV once at the reappearance of TOF 0.3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex 0.5</arm_group_label>
    <description>Sugammadex group: sugammadex 0.5 mg/kg IV once at the reappearance of TOF 0.3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex 1.0</arm_group_label>
    <description>Sugammadex group: sugammadex 1.0 mg/kg IV once at the reappearance of TOF 0.3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex 2.0</arm_group_label>
    <description>Sugammadex group: sugammadex 2.0 mg/kg IV once at the reappearance of TOF 0.3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neostigmine 10</arm_group_label>
    <description>Neostigmine group: neostigmine 10 µg/kg IV once at the reappearance of TOF 0.3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neostigmine 25</arm_group_label>
    <description>Neostigmine group: neostigmine 25 µg/kg IV once at the reappearance of TOF 0.3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neostigmine 40</arm_group_label>
    <description>Neostigmine group: neostigmine 40 µg/kg IV once at the reappearance of TOF 0.3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neostigmine 55</arm_group_label>
    <description>Neostigmine group: neostigmine 55 µg/kg IV once at the reappearance of TOF 0.3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neostigmine 70</arm_group_label>
    <description>Neostigmine group: neostigmine 70 µg/kg IV once at the reappearance of TOF 0.3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <description>Placebo group: Saline 0.9% IV once at the reappearance of TOF 0.3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of either :&#xD;
Sugammadex 0.125 mg/kg (sugammadex 0.125) Sugammadex 0.25 mg/kg (sugammadex 0.25) Sugammadex 0.5 mg/kg (sugammadex 0.5) Sugammadex 1.0 mg/kg (sugammadex 1.0) Sugammadex 2.0 mg/kg (sugammadex 2.0)</description>
    <arm_group_label>Sugammadex 0.25</arm_group_label>
    <arm_group_label>Sugammadex 0.5</arm_group_label>
    <arm_group_label>Sugammadex 1.0</arm_group_label>
    <arm_group_label>Sugammadex 2.0</arm_group_label>
    <arm_group_label>sugammadex 0.125</arm_group_label>
    <other_name>Bridion</other_name>
    <other_name>Org 25969</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine</intervention_name>
    <description>At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of either :&#xD;
Neostigmine 10 µg/kg (Neostigmine 10) Neostigmine 25 µg/kg (Neostigmine 25) Neostigmine 40 µg/kg (Neostigmine 40) Neostigmine 55 µg/kg (Neostigmine 55) Neostigmine 70 µg/kg (Neostigmine 70)&#xD;
Atropine will be administered with Neostigmine at a half dose of Neostigmine administered through an intravenous line with brisk flow.</description>
    <arm_group_label>Neostigmine 10</arm_group_label>
    <arm_group_label>Neostigmine 25</arm_group_label>
    <arm_group_label>Neostigmine 40</arm_group_label>
    <arm_group_label>Neostigmine 55</arm_group_label>
    <arm_group_label>Neostigmine 70</arm_group_label>
    <other_name>Prostigmin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline 0.9%</intervention_name>
    <description>At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of saline 0.9%.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        people scheduled for elective surgery&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1 age of 18 to 65 yr,&#xD;
&#xD;
          -  2 body mass index 18.5 to 25.0 kg/m2,&#xD;
&#xD;
          -  3 American Society of Anesthesiologists physical status I to III&#xD;
&#xD;
          -  4 scheduled for elective surgery with an expected duration of at least 60min under&#xD;
             general anesthesia with intubation of the trachea or laryngeal mask&#xD;
&#xD;
          -  5 patients having given informed consent to the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1 patients who had participated in another clinical trial within 1 month&#xD;
&#xD;
          -  2 Patients with suspected difficult airway, bronchial asthma, chronic obstructive&#xD;
             pulmonary disease&#xD;
&#xD;
          -  3 known neuromuscular disease&#xD;
&#xD;
          -  4 suspected malignant hyperthermia&#xD;
&#xD;
          -  5 hepatic or renal dysfunction&#xD;
&#xD;
          -  6 glaucoma&#xD;
&#xD;
          -  7 allergy to the medication that used in this trial&#xD;
&#xD;
          -  8 taking medicaments that might influence the effect of NMB agents&#xD;
&#xD;
          -  9 pregnant, or breastfeeding state&#xD;
&#xD;
          -  10 taking medication known to alter the effect of neuromuscular blocking agents(&#xD;
             toremifene .etc)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Guangzhou Military Region General Hospital, Department of Anesthesiology</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Pongrácz A, Szatmári S, Nemes R, Fülesdi B, Tassonyi E. Reversal of neuromuscular blockade with sugammadex at the reappearance of four twitches to train-of-four stimulation. Anesthesiology. 2013 Jul;119(1):36-42. doi: 10.1097/ALN.0b013e318297ce95.</citation>
    <PMID>23665915</PMID>
  </reference>
  <reference>
    <citation>Schaller SJ, Fink H, Ulm K, Blobner M. Sugammadex and neostigmine dose-finding study for reversal of shallow residual neuromuscular block. Anesthesiology. 2010 Nov;113(5):1054-60. doi: 10.1097/ALN.0b013e3181f4182a.</citation>
    <PMID>20885293</PMID>
  </reference>
  <reference>
    <citation>Kaufhold N, Schaller SJ, Stäuble CG, Baumüller E, Ulm K, Blobner M, Fink H. Sugammadex and neostigmine dose-finding study for reversal of residual neuromuscular block at a train-of-four ratio of 0.2 (SUNDRO20)†,. Br J Anaesth. 2016 Feb;116(2):233-40. doi: 10.1093/bja/aev437.</citation>
    <PMID>26787792</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 10, 2018</study_first_submitted>
  <study_first_submitted_qc>August 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2018</study_first_posted>
  <last_update_submitted>August 9, 2020</last_update_submitted>
  <last_update_submitted_qc>August 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou General Hospital of Guangzhou Military Command</investigator_affiliation>
    <investigator_full_name>bo xu</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>sugammadex neostigmine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

